{
    "pmcid": "7959386",
    "qa_pairs": {
        "How does the biparatopic fusion strategy enhance the neutralization potency of nanobodies?": [
            "By combining two different binding sites to increase overall binding affinity and neutralization potential",
            "By altering the conformation of the receptor-binding motif (RBM)",
            "By increasing the size of the nanobody to cover more surface area",
            "By using random mutagenesis to improve binding strength"
        ],
        "What is a suggested future direction for enhancing the potency of nanobody constructs according to the study?": [
            "Creating hexavalent sybodies by combining multiple copies of SR31 and other potent nanobodies",
            "Developing monoclonal antibodies with higher specificity",
            "Increasing the molecular weight of nanobodies for better stability",
            "Utilizing viral vectors to deliver nanobodies in vivo"
        ],
        "What is one potential application of the SR31 nanobody mentioned in the study?": [
            "Serving as a general affinity-enhancer for both therapeutic and detection purposes",
            "Acting as a vaccine adjuvant to boost immune response",
            "Functioning as a standalone antiviral treatment",
            "Being used as a diagnostic marker for SARS-CoV-2 infection"
        ],
        "What is the dissociation constant (KD) of the SR31 nanobody, indicating its binding affinity?": [
            "5.6 nM",
            "10.2 nM",
            "3.4 nM",
            "7.8 nM"
        ],
        "What is the primary target of the SR31 nanobody developed in the study?": [
            "A conserved, hydrophobic site on the RBD of the SARS-CoV-2 spike protein",
            "The receptor-binding motif (RBM) of the SARS-CoV-2 spike protein",
            "The N-terminal domain of the SARS-CoV-2 spike protein",
            "The S2 subunit of the SARS-CoV-2 spike protein"
        ]
    }
}